The Effects of C. lacerata on Insulin Resistance in Type 2 Diabetes Patients

Table 4

Subgroup analysis of glycemic markers based on HOMA-IR.

(a)

							value^c
	Placebo group ()			C. lacerata group ()
	Week 0	Week 12	value^a	Week 0	Week 12	value^a
Hba1c (%)			0.349			0.064	0.108
HOMA-IR			0.112			0.037	0.459
HOMA-beta			0.555			0.477	0.325
QUICKI			0.124			0.026	0.40
FPG (mg/dL)			0.127			0.721	0.186
2 hr Glc (mg/dL)			0.825			0.695	0.395
F.C-pep (ng/mL)			0.266			0.013	0.008
P.C-Pep (ng/mL)			0.864			0.025	0.185
F.PI (mcIU/mL)			0.094			0.024	0.202
P.PI (mcIU/mL)			0.701			0.107	0.289

(b)

							value^c
	Placebo group ()			C. lacerata group ()
	Week 0	Week 12	value^a	Week 0	Week 12	value^a
Hba1c (%)			0.011			0.944	0.325
HOMA-IR			0.025			0.123	0.982
HOMA-beta			0.173			0.374	0.279
QUICKI			0.116			0.213	0.743
FPG (mg/dL)			0.249			0.263	0.155
2 hr Glc (mg/dL)			0.161			0.953	0.740
F.C-pep (ng/mL)			0.123			0.767	0.158
P.C-pep (ng/mL)			0.889			0.314	0.149
F.PI (mcIU/mL)			0.233			0.212	0.518
P.PI (mcIU/mL)			0.575			0.441	0.094

Data are presented as (SD). ^aNonparametric paired Wilcoxon signed-rank test was used to compare baseline data to those at 12 weeks in each group. ^cQuade’s rank analysis of covariates adjusted for each glycemic marker initial values was performed to estimate the statistical differences between the placebo and C. lacerata groups’ changes in glycemic markers after the 12-week intervention. Statistically significant values are indicated ^awithin-group value < 0.05 and ^cbetween-group value < 0.05. HOMA-IR: homeostasis model assessment for insulin resistance; QUICKI: quantitative insulin-sensitivity check index; FPG: fasting plasma glucose; 2 hr Glc: 2-hour plasma glucose; F.C-pep: fasting C-peptide; P.C-pep: postprandial C-peptide; F.PI: fasting plasma insulin; P.PI: postprandial plasma insulin.